Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Why Indonesia is vaccinating its working population first, not the elderly

The country plans to begin mass inoculations with a vaccine developed by China's Sinovac Biotech

Stanley Widianto,Tabita Diela
Monday 04 January 2021 10:42 GMT
Comments
The country plans to begin mass inoculations with a vaccine developed by China's Sinovac Biotech
The country plans to begin mass inoculations with a vaccine developed by China's Sinovac Biotech (via REUTERS)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

As Indonesia prepares to begin mass inoculations against Covid-19, its plan to prioritise working age adults over the elderly, aiming to reach herd immunity fast and revive the economy, will be closely watched by other countries.

Several countries such as the United States and Britain that have already begun vaccinations are giving priority to elderly people who are more vulnerable to the respiratory disease.

The following are experts' views on merits and risks of the Indonesian approach, under which working age adults will be vaccinated after frontline health workers and public servants.

WHY 18-59 YEAR-OLDS FIRST?

Indonesia, which plans to begin mass inoculations with a vaccine developed by China's Sinovac Biotech, says it does not have enough data yet of the vaccine's efficacy on elderly people, as clinical trials underway in the country involves people aged 18-59.

“We're not bucking the trend,” said Siti Nadia Tarmizi, a senior health ministry official, adding authorities would await recommendations from the country's drug regulators to decide on vaccination plans for the elderly.

While Britain and the United States began immunisations with a shot developed by Pfizer Inc and its partner BioNTech that showed it works well in people of all ages, Indonesia has initial access only to the Sinovac vaccine.

The Southeast Asian country has a deal to receive 125.5 million doses of Sinovac's CoronaVac shot, and a first batch of 3 million doses are already in the country.

Shipments of the Pfizer vaccine to the country are expected to begin from the third quarter, while a vaccine developed by AstraZeneca and Oxford University will start being distributed in the second quarter.

“I don't think anybody can get too dogmatic about what is the right approach,” said Peter Collignon, professor of infectious diseases at Australian National University, adding that Indonesia's strategy could slow the spread of the disease, although it may not affect mortality rates.

“Indonesia doing it different to the US and Europe is of value, because it will tell us (whether) you'll see a more dramatic effect in Indonesia than Europe or US because of the strategy they're doing, but I don't think anybody knows the answer.”

Professor Dale Fisher from the Yong Loo Lin School of Medicine at the National University of Singapore said he understood the rationale of Indonesia's approach.

“Younger working adults are generally more active, more social and travel more so this strategy should decrease community transmission faster than vaccinating older individuals,” he said.

“Of course older people are more at risk of severe disease and death so vaccinating those has an alternative rationale. I see merit in both strategies.”

WILL IT HELP ACHIEVE HERD IMMUNITY QUICKLY?

By vaccinating more socially mobile and economically active groups first, Indonesian government officials hope the government can quickly reach herd immunity.

Budi Gunadi Sadikin, Indonesia's health minister, said the country needs to vaccinate 181.5 million people, or roughly 67% of its population, to reach herd immunity, and requires almost 427 million doses of vaccines, assuming a double-dose regimen and a 15% wastage rate.

Some experts are skeptical about reaching herd immunity, as more research needs to be done to ascertain whether or not vaccinated people can transmit the virus.

“There could be the risk of people still capable of spreading the disease to the others,” said Hasbullah Thabrany, chief of the Indonesian Health Economic Association.

WILL IT HELP ECONOMIC RECOVERY?

Economists have argued a successful vaccination programme covering around 100 million people will help jumpstart the economy, as they are more likely to resume economic activity such as spending and production.

Faisal Rachman, an economist with Bank Mandiri, said that the 18-59 age group has consumption needs that are higher than other groups.

“They could jack up the economic recovery faster because household consumption contributes more than 50% to Indonesia's economy,” he said, warning that rising COVID-19 cases in the country could also risk lowering people's confidence.

The pandemic pushed Indonesia, Southeast Asia's largest economy, into its first recession in more than two decades last year, with the government estimating a contraction of as much as 2.2%.

Reuters

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in